Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sanofi CEO Paul Hudson, speaking at the BofA Global Healthcare Conference, provided an update on the company's pipeline, noting mixed results for itepekimab but expressing significant excitement over positive feedback for amlitelimab and brivekimig in immunology. Hudson also addressed the PDUFA extension for tolebrutinib, indicating confidence in the GEMINI 1 and 2 data for disability progression, and reaffirmed the company's strong underlying performance despite these specific pipeline developments.

Analysis

At the Bank of America Global Healthcare Conference, Sanofi's CEO Paul Hudson presented a mixed but ultimately optimistic outlook on the company's pipeline. A key challenge highlighted was the itepekimab readout, which yielded one positive and one negative result, creating a 'complicated situation' that the CEO found 'irritating.' In stark contrast, Hudson expressed significant excitement for the immunology portfolio, citing 'extraordinary' feedback for amlitelimab and enthusiasm for the bispecific NHS, brivekimig. Regarding tolebrutinib, he addressed the PDUFA date extension not as a setback, but as a positive development allowing the FDA more time to review the robust GEMINI 1 and 2 data, which he noted showed an impact on disability progression almost as strong as in the secondary progressive population. Despite specific pipeline frustrations, the CEO affirmed that the company's 'underlying performance is strong,' signaling confidence driven by the promising immunology assets and the potential of tolebrutinib post-approval.

Key Decisions for Investors

• Investors should focus on the high-potential immunology assets, amlitelimab and brivekimig, as management's commentary suggests these are key future growth drivers that may offset disappointments elsewhere in the pipeline.
• The extended PDUFA timeline for tolebrutinib introduces a near-term regulatory risk; however, a positive FDA decision based on the strong GEMINI data could serve as a significant stock catalyst, making the outcome a critical event to monitor.
• Given the mixed results for itepekimab, it is prudent to weigh the CEO's overall optimism against the inherent R&D risks, and to evaluate Sanofi's valuation in the context of both its promising immunology pipeline and recent clinical setbacks.